|
1
|
Buckner JC, Brown PD, O'Neill BP, Meyer
FB, Wetmore CJ and Uhm JH: Central nervous system tumors. Mayo Clin
Proc. 82:1271–1286. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Salacz ME, Watson KR and Schomas DA:
Glioblastoma: Part I. Current state of affairs. Mol Med.
108:187–194. 2011.PubMed/NCBI
|
|
3
|
Salacz ME, Watson KR and Schomas DA:
Glioblastoma. Part II: future directions. Mol Med. 108:289–291.
2011.PubMed/NCBI
|
|
4
|
Louis DN, Ohgaki H, Wiestler OD and
Cavenee WK: WHO Classification of Tumours of the Central Nervous
System. World Health Organization; 2007
|
|
5
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar
|
|
7
|
Karlsson R, Pedersen ED, Wang Z and
Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys
Acta. 1796:91–98. 2009.PubMed/NCBI
|
|
8
|
Boettner B and Van Aelst L: The role of
Rho GTPases in disease development. Gene. 286:155–174. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ridley AJ: Rho proteins and cancer. Breast
Cancer Res Treat. 84:13–19. 2004. View Article : Google Scholar
|
|
10
|
Hornstein I, Pikarsky E, Groysman M, Amir
G, Peylan-Ramu N and Katzav S: The haematopoietic specific signal
transducer Vav1 is expressed in a subset of human neuroblastomas. J
Pathol. 199:526–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Wyckoff JB, Frohlich VC, et al:
Single cell behavior in metastatic primary mammary tumors
correlated with gene expression patterns revealed by molecular
profiling. Cancer Res. 62:6278–6288. 2002.PubMed/NCBI
|
|
12
|
Kim TY, Vigil D, Der CJ and Juliano RL:
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in
regulation of the cytoskeleton and cell motility. Cancer Metastasis
Rev. 28:77–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawai K, Seike J, Iino T, et al:
START-GAP2/DLC2 is localized in focal adhesions via its N-terminal
region. Biochem Biophys Res Commun. 380:736–741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rittinger K, Walker PA, Eccleston JF, et
al: Crystal structure of a small G protein in complex with the
GTPase-activating protein rhoGAP. Nature. 388:693–697. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yau TO, Leung TH, Lam S, et al: Deleted in
liver cancer 2 (DLC2) was dispensable for development and its
deficiency did not aggravate hepatocarcinogenesis. PLoS One.
4:e65662009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tcherkezian J and Lamarche-Vane N: Current
knowledge of the large RhoGAP family of proteins. Biol Cell.
99:67–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Soccio RE and Breslow JL: StAR-related
lipid transfer (START) proteins: mediators of intracellular lipid
metabolism. J Biol Chem. 278:22183–22186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian X, Li G, Asmussen HK, et al:
Oncogenic inhibition by a deleted in liver cancer gene requires
cooperation between tensin binding and Rho-specific
GTPase-activating protein activities. Proc Natl Acad Sci USA.
104:9012–9017. 2007. View Article : Google Scholar
|
|
19
|
Li H, Fung KL, Jin DY, et al: Solution
structures, dynamics, and lipid-binding of the sterile alpha-motif
domain of the deleted in liver cancer 2. Proteins. 67:1154–1166.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao YC and Lo SH: Deleted in liver
cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J
Biochem Cell Biol. 40:843–847. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ching YP, Wong CM, Chan SF, et al: Deleted
in liver cancer (DLC) 2 encodes a RhoGAP protein with growth
suppressor function and is underexpressed in hepatocellular
carcinoma. J Biol Chem. 278:10824–10830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ng DC, Chan SF, Kok KH, et al:
Mitochondrial targeting of growth suppressor protein DLC2 through
the START domain. FEBS Lett. 580:191–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
|
|
24
|
Leung TH, Ching YP, Yam JW, et al: Deleted
in liver cancer 2 (DLC2) suppresses cell transformation by means of
inhibition of RhoA activity. Proc Natl Acad Sci USA.
102:15207–15212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiaorong L, Wei W, Liyuan Q and Kaiyan Y:
Underexpression of deleted in liver cancer 2 (DLC2) is associated
with overexpression of RhoA and poor prognosis in hepatocellular
carcinoma. BMC Cancer. 8:2052008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shih YP, Takada Y and Lo SH: Silencing of
DLC1 upregulates PAI-1 expression and reduces migration in normal
prostate cells. Mol Cancer Res. 10:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leung LH, Wong WK, Cheng AC, et al: A new
approach to computing normal tissue complication probability of an
intensity-modulated radiotherapy treatment with stereotactic
radiotherapy boost of nasopharyngeal carcinoma: a case study. Med
Dosim. 36:138–144. 2011. View Article : Google Scholar
|
|
28
|
Zheng B, Fiumara P, Li YV, et al: MEK/ERK
pathway is aberrantly active in Hodgkin disease: a signaling
pathway shared by CD30, CD40, and RANK that regulates cell
proliferation and survival. Blood. 102:1019–1027. 2003. View Article : Google Scholar : PubMed/NCBI
|
